Related Posts
InfraVia Growth invests in Orakl Oncology to make cancer drug response predictable before clinical trials
InfraVia Growth invests in Orakl Oncology to make cancer drug response predictable before clinical trials
The Series A, co-led by Norrsken VC and Singular, follows a breakthrough: Orakl's AI predicted cancer clinical trial outcomes prospectively with 90% accuracy.
WeAreBlow12 November 2026
Supporting finance teams through transformation and growth
Supporting finance teams through transformation and growth
As businesses scale, finance functions play a critical role in enabling performance and supporting long-term value creation.
WeAreBlow29 October 2026
InfraVia Growth Equity AGM 2026
InfraVia Growth Equity AGM 2026
In October 2026, we welcomed our investors to Paris for InfraVia’s Growth Equity annual investor meeting.
WeAreBlow28 October 2026
